Michel Revel
Known title: CSO and DirectorCIK: 0002095518
Michel Revel's purchase track record
Michel Revel has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/27/2026 | NCEL | $150K | -7.0% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NCEL | ▲ Buy | Open Market | 54,545 | $150K | 4/27/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
NewCelX Management to Attend Breakthrough T1D Congress
NewCelX management plans to attend the Breakthrough T1D Congress in Philadelphia to discuss its work on developing a cure for Type 1 Diabetes. This event highlights the company's ongoing research efforts in a critical area of medical science. The stock is currently trading near its 52-week low, reflecting the long-term nature of such development.
NewCelX Management to Attend Breakthrough T1D Congress. NewCelX management plans to attend the Breakthrough T1D Congress in Philadelphia to discuss its work on developing a cure for Type 1 Diabetes. This event highlights the company's ongoing research efforts in a critical area of medical science. The stock is currently trading near its 52-week low, reflecting the long-term nature of such development.